Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $491.90 million. The enterprise value is $302.97 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 16.57 million shares outstanding. The number of shares has increased by 17.67% in one year.
| Current Share Class | 16.57M |
| Shares Outstanding | 16.57M |
| Shares Change (YoY) | +17.67% |
| Shares Change (QoQ) | +49.79% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 51.99% |
| Float | 10.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.94 |
| Forward PS | 16.43 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.25
| Current Ratio | 3.25 |
| Quick Ratio | 3.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.06 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -19.32% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -49.53% |
| Weighted Average Cost of Capital (WACC) | 19.50% |
| Revenue Per Employee | $727,066 |
| Profits Per Employee | -$1.12M |
| Employee Count | 137 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -115,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +222.72% in the last 52 weeks. The beta is 1.64, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.64 |
| 52-Week Price Change | +222.72% |
| 50-Day Moving Average | 30.53 |
| 200-Day Moving Average | 16.52 |
| Relative Strength Index (RSI) | 42.62 |
| Average Volume (20 Days) | 330,644 |
Short Selling Information
The latest short interest is 977,108, so 5.90% of the outstanding shares have been sold short.
| Short Interest | 977,108 |
| Short Previous Month | 748,699 |
| Short % of Shares Out | 5.90% |
| Short % of Float | 9.48% |
| Short Ratio (days to cover) | 4.00 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $99.61 million and -$153.60 million in losses. Loss per share was -$15.87.
| Revenue | 99.61M |
| Gross Profit | -66.81M |
| Operating Income | -87.10M |
| Pretax Income | -153.72M |
| Net Income | -153.60M |
| EBITDA | -79.84M |
| EBIT | -87.10M |
| Loss Per Share | -$15.87 |
Full Income StatementBalance Sheet
The company has $202.56 million in cash and $13.63 million in debt, with a net cash position of $188.93 million or $11.40 per share.
| Cash & Cash Equivalents | 202.56M |
| Total Debt | 13.63M |
| Net Cash | 188.93M |
| Net Cash Per Share | $11.40 |
| Equity (Book Value) | -66.89M |
| Book Value Per Share | -5.11 |
| Working Capital | 148.90M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 7.26M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is -67.07%, with operating and profit margins of -87.44% and -154.21%.
| Gross Margin | -67.07% |
| Operating Margin | -87.44% |
| Pretax Margin | -154.32% |
| Profit Margin | -154.21% |
| EBITDA Margin | -80.15% |
| EBIT Margin | -87.44% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.67% |
| Shareholder Yield | -17.67% |
| Earnings Yield | -31.23% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Sutro Biopharma is $46.55, which is 56.79% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.55 |
| Price Target Difference | 56.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 7.59% |
| EPS Growth Forecast (5Y) | -26.39% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |
